Please select your page
  • Slide
  • Slide
  • Slide

Cardiovascular disease (CVD) is the leading cause of death globally: more people die annually from CVDs than from any other cause.

Today, cardiovascular diseases are responsible annually for the death of 17.3 million people worldwide, representing approximately one in every three deaths. It represents an enormous area in terms of unmet need and commercial opportunity with $30 billion in 2013 global sales from the LDL-lowering segment alone.
Current LDL-focused therapies for CVD only reduce cardiovascular events by 25-35%, leaving significant opportunity for further improvements.
Therapies focused on increasing HDL, both acutely and chronically, represent the next frontier in the treatment of CVD. Clinical evidence supports the concept that elevating HDL can rapidly reduce atherosclerotic plaque and the risk of cardiovascular events.
To address this significant unmet medical need, Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and HDL elevators for patients with low HDL. Cerenis’ CER-001, the only product that acts like a natural HDL particle, has the potential to be the first to market recombinant HDL.


Cerenis Therapeutics Holding SA
33-43 av. Georges Pompidou – Bât. D2
31130 Balma – France
Tel. +33 5 62 24 97 06
Fax +33 5 61 57 34 12


Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143